Physician profile
Eric T Pride
NPI 1417950627
$1,790.62
in general payments reported to CMS, 2019-2025
21 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $92.26 · 2021: $132 · 2022: $601 · 2023: $19.16 · 2024: $30.87 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $215.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $355.48 | 2019-2022 | |
| Medtronic, INC. | $201.42 | 2021-2025 | Symplicity G3 |
| Amgen INC. | $173.26 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $159.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $142.63 | 2019-2022 | |
| Baxter Healthcare | $137.71 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $108.15 | 2019 | |
| Bard Peripheral Vascular, INC. | $104.51 | 2019 | |
| Fresenius USA Marketing, INC. | $78.39 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $45.77 | 2022 | |
| Mallinckrodt Hospital Products INC. | $44.68 | 2020-2022 | |
| Glaxosmithkline, LLC. | $39.37 | 2022-2023 | Jesduvroq |
| Horizon Therapeutics Plc | $39.05 | 2019-2022 | |
| Outset Medical INC | $30.87 | 2024 | |
| Travere Therapeutics, INC. | $29.83 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $21.65 | 2022 | |
| Daiichi Sankyo INC. | $19.40 | 2019 | |
| Akebia Therapeutics INC | $18.98 | 2019 | |
| Ani Pharmaceuticals, INC. | $16.30 | 2022 | |
| Opko Pharmaceuticals, LLC | $12.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Pride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.